United States

Orexo AB (ORX.ST)

ORX.ST on Stockholm Stock Exchange

24 May 2017
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Orexo Q1 operating loss narrows
Thursday, 20 Apr 2017 02:00am EDT 

April 20 (Reuters) - Orexo AB :Q1 total net revenues SEK 127.4 million (151.0).Q1 Zubsolv net revenue SEK 114.1 million (98.4).Q1 EBIT SEK -23.2 million (-26.2).Says guidance issued in connection with full year report 2016 confirmed.  Full Article

Orexo swings to net profit in Q4
Thursday, 26 Jan 2017 02:00am EST 

Orexo AB : Q4 total net revenues msek 184.7 (228.3) . Q4 zubsolv net revenue msek 128.2 (120.3) .Q4 net earnings msek 33.3 (-51.8).  Full Article

Orexo Q2 net earnings in line with expectations
Tuesday, 12 Jul 2016 02:00am EDT 

Orexo AB : Q2 total net revenues MSEK 188.2 (126.5) . Q2 earnings after tax MSEK 5.0 (-84.6). . Says effective July 1st Zubsolv is only preferred buprenorphine/naloxone product within largest fee for service (ffs) medicaid program in U.S., state of Maryland .Reuters poll: Orexo Q2 revenues were seen at 185 million SEK, net result 5 million SEK [nL8N19U1PZ].  Full Article

AstraZeneca acquires rights to Orexo OX-CLI project
Thursday, 17 Mar 2016 03:00am EDT 

Orexo AB:Says AstraZeneca acquires all rights to Orexo's OX-CLI project.Says i‍n accordance to option agreement from 2013, Orexo will receive a payment of $5 million for rights to OX-CLI.Says ‍future milestone payments can be expected when OX-CLI meets defined development and commercial objectives.Says ‍in addition to milestones Orexo will receive a tiered single digit royalty on future net-revenue​​.  Full Article

Orexo says gets Abstral milestone payment, takes SEK 62 mln charge in Q4
Friday, 11 Dec 2015 02:00am EST 

Orexo AB:Says receives MGBP 5 milestone payment for Abstral in Europe and records OX-MPI non-cash impairment charge of MSEK 62.Says still considers OX-MPI an attractive asset and will continue the dialogue with potential partners, however as part of the annual impairment assessment it has been decided to fully write down the value of the asset.Says both events will have full financial impact in the fourth quarter of 2015.  Full Article

Orexo settles Abstral U.S. patent litigation with Actavis
Tuesday, 27 Oct 2015 03:30am EDT 

Orexo AB:Orexo settles Abstral U.S. patent litigation with Actavis.Says agreement allows Actavis to enter market in June 2018, or earlier under certain conditions.Says Orexo's patents listed in FDA's Orange Book for Abstral expire in September 2019.Says agreement settles the patent infringement litigation commenced early this year by Orexo following Actavis' filing of an Abbreviated New Drug Application seeking approval to market generic versions of Abstral (fentanyl) sublingual tablets in the U.S.  Full Article

Orexo says new U.S. regulations expand access to treatment of opioid dependence
Friday, 18 Sep 2015 02:30am EDT 

Orexo AB:Says new regulations will expand access to treatment of opioid dependence in the U.S.  Full Article

Orexo AB says gets U.S. FDA approval for Zubsolv
Tuesday, 11 Aug 2015 02:30am EDT 

Orexo AB:Says U.S. FDA approves Zubsolv for induction of buprenorphine maintenance therapy in patients suffering from opioid dependence.  Full Article

Orexo AB announces issue and repurchase of class C shares
Wednesday, 17 Jun 2015 02:00am EDT 

Orexo AB:Says it has resolved to issue and immediately thereafter repurchase 135,000 class C shares.Shares are issued and repurchased in accordance with the long-term incentive program, LTIP 2015, which was adopted by the annual general meeting on April 15, 2015.  Full Article

More From Around the Web

BRIEF-Orexo Q1 operating loss narrows

* Says guidance issued in connection with full year report 2016 confirmed Source text for Eikon: Further company coverage: (Stockholm Newsroom)